Why the study?
Does aspirin alone or in combination with dipyridamole prolong platelet survival in insulin-dependent diabetic patients with severe retinopathy?
Does aspirin alone or in combination with dipyridamole prolong platelet survival in insulin-dependent diabetic patients with severe retinopathy?
High-dose aspirin combined with dipyridamole significantly prolongs platelet survival in diabetic patients with severe retinopathy, suggesting that reducing aspirin doses below 1 g/day in this combination may reduce its antithrombotic efficacy on this surrogate marker.
Answers are grounded in this paper and cite their sources.
High-dose aspirin/dipyridamole prolongs platelet survival in diabetic retinopathy; supports ~1 g/day dosing on this surrogate but needs outcome trials.
Platelet survival in 27 insulin-dependent diabetic patients with severe retinopathy was studied in a double-blind cross-over trial using placebo, aspirin (990 mg/day) and a combination of dipyridamole (225 mg/day) with aspirin at two dosage levels (330 mg and 990 mg/day). 2. Twenty patients (group I) had 51Cr-labelled-platelet survival after treatment with placebo and the high-dose-aspirin/dipyridamole combination. The remaining seven patients (group II) had platelet-regeneration times measured after each of the four treatment periods. 3. Treatment of group I patients with the high-dose-aspirin/dipyridamole combination resulted in significant (P less than 0.001) prolongation of platelet survival from 7.3 +/- 0.2 (mean +/- SEM days to 8.4 +/- 0.1 days. 4. In group II patients, when compared with the mean placebo result of 7.2 +/- 0.2 days, the mean aspirin-labelled-platelet-regeneration time was significantly (P less than 0.01) longer only after high-dose-aspirin/dipyridamole (9.8 +/- 0.5 days) but not after low-dose-aspirin/dipyridamole (8.3 +/- 0.5 days) or aspirin alone (7.3 +/- 0.3 days). 5. These results suggest that it may be premature to consider reducing the dose of aspirin in aspirin/dipyridamole combinations below 1 g/day when used as antithrombotic therapy.
No takes yet. Share an insight, caveat, or question.
Tindall et al. (1982) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: